ArticleCureus2025
Oral Eplerenone for Exudative Retinal Detachment Secondary to Central Serous Chorioretinopathy: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Central serous chorioretinopathy (CSCR) is a retinal disorder characterized by subretinal fluid (SRF) accumulation, and its bullous variant represents a rare and severe form often lacking standardized treatment. We report a case of a patient with short stature and normal cortisol and growth hormone levels, diagnosed with the bullous variant of CSCR and treated with oral spironolactone, a mineralocorticoid receptor (MR) antagonist. The patient showed marked resolution of exudative retinal detachment (RD) and improvement in visual acuity within one month of initiating therapy with 50 mg/day of spironolactone. This case highlights the potential role of oral spironolactone as an effective and less invasive therapeutic option for managing the bullous variant of CSCR, offering a promising alternative to more aggressive interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.